Key statistics
On Friday, BridgeBio Pharma Inc (2CL:FRA) closed at 23.32, 11.05% above the 52 week low of 21.00 set on Aug 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.77 |
---|---|
High | 23.77 |
Low | 23.32 |
Bid | 23.76 |
Offer | 24.25 |
Previous close | 23.95 |
Average volume | 759.80 |
---|---|
Shares outstanding | 188.03m |
Free float | 151.35m |
P/E (TTM) | -- |
Market cap | 5.03bn USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 15:14 BST.
More ▼
Announcements
- BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
- BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
- BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
- BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
- BridgeBio Pharma to Participate in September Investor Events
- BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
- BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
- BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
More ▼